Selcia and Gilead Sciences have entered into a drug discovery partnership that will focus on medicines to treat liver diseases.

Building on an established partnership, Selcia will provide its integrated drug discovery services to support Gilead’s liver disease research programmes.

The collaboration will focus on delivering candidates for clinical studies.

Selcia managing director Dr Hans Fliri said that the company was looking forward to support Gilead in the search for new drugs to treat liver diseases.